NASDAQ:ICAD - iCAD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.50
  • Forecasted Upside: 355.80 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.62
▼ -0.2 (-5.24%)

This chart shows the closing price for ICAD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iCAD Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICAD

Analyst Price Target is $16.50
▲ +355.80% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for iCAD in the last 3 months. The average price target is $16.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 355.80% upside from the last price of $3.62.

This chart shows the closing price for ICAD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in iCAD. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/18/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2022Lake Street CapitalLower Price Target$22.00 ➝ $13.00High
1/18/2022GuggenheimDowngradeBuy ➝ NeutralHigh
1/5/2022JMP SecuritiesReiterated RatingBuy$13.00High
1/5/2022OppenheimerLower Price TargetOutperform$22.00 ➝ $16.00Low
1/5/2022Lake Street CapitalLower Price TargetBuy ➝ Buy$25.00 ➝ $22.00Low
11/10/2021BTIG ResearchReiterated RatingBuy$24.00Medium
11/10/2021JMP SecuritiesReiterated RatingBuy$22.00 ➝ $18.00High
8/30/2021OppenheimerReiterated RatingBuy$24.00High
4/22/2021GuggenheimInitiated CoverageBuy$24.00Low
3/23/2021BTIG ResearchInitiated CoverageBuy$25.00High
2/26/2021B. RileyBoost Price TargetBuy$18.00 ➝ $23.00High
2/25/2021OppenheimerInitiated CoverageOutperform$27.00High
2/25/2021Craig HallumBoost Price TargetBuy$15.00 ➝ $22.00High
2/25/2021Lake Street CapitalBoost Price TargetBuy$17.00 ➝ $21.00High
1/28/2021Cantor FitzgeraldInitiated CoverageOverweight$19.00High
12/15/2020B. RileyBoost Price TargetBuy$15.00 ➝ $18.00High
12/11/2020Lake Street CapitalBoost Price TargetBuy$14.00 ➝ $17.00High
12/3/2020B. RileyInitiated CoverageBuy$15.00High
2/13/2020Craig HallumBoost Price TargetBuy$9.00 ➝ $15.00High
2/5/2020JMP SecuritiesInitiated CoverageOutperform$15.00Medium
1/9/2020Lake Street CapitalInitiated CoverageBuy$14.00High
12/20/2019Dougherty & CoInitiated CoverageBuy$10.00High
7/25/2017LaidlawReiterated RatingBuy$11.00Medium
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/21/2021
  • 2 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
11/20/2021
  • 2 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
1/19/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/18/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/19/2022
  • 6 very positive mentions
  • 15 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
5/19/2022

Current Sentiment

  • 6 very positive mentions
  • 15 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

iCAD logo
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Today's Range

Now: $3.62
Low: $3.58
High: $3.89

50 Day Range

MA: $3.80
Low: $3.02
High: $4.49

52 Week Range

Now: $3.62
Low: $2.91
High: $19.00

Volume

148,559 shs

Average Volume

229,049 shs

Market Capitalization

$91.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of iCAD?

The following Wall Street research analysts have issued stock ratings on iCAD in the last year: BTIG Research, Guggenheim, JMP Securities, Lake Street Capital, Oppenheimer Holdings Inc., StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for ICAD.

What is the current price target for iCAD?

0 Wall Street analysts have set twelve-month price targets for iCAD in the last year. Their average twelve-month price target is $16.50, suggesting a possible upside of 355.8%.
View the latest price targets for ICAD.

What is the current consensus analyst rating for iCAD?

iCAD currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ICAD will outperform the market and that investors should add to their positions of iCAD.
View the latest ratings for ICAD.

How do I contact iCAD's investor relations team?

iCAD's physical mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company's listed phone number is (603) 882-5200 and its investor relations email address is [email protected] The official website for iCAD is www.icadmed.com. Learn More about contacing iCAD investor relations.